# Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

> **NCT06316297** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 800 (estimated)

## Conditions studied

- Acne

## Interventions

- **BIOLOGICAL:** Acne mRNA vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06316297
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06316297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06316297, "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06316297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*